[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · see citing works

The Corticosteroid Receptor Hypothesis of Depression

Holsboer, F. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00159-7 · Cited by 2,181 · see citing works

Solid Phase Peptide Synthesis

Stewart, J. M. (1976) · Journal of Macromolecular Science Part A - Chemistry · doi:10.1080/00222337608068099 · Cited by 1,770 · see citing works

Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin

Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · see citing works

Increased Numbers of Corticotropin-Releasing Hormone Expressing Neurons in the Hypothalamic Paraventricular Nucleus of Depressed Patients

Raadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667 · see citing works

Solid-Phase Peptide Synthesis. III. An Improved Synthesis of Bradykinin*

Merrifield, R. B. (1964) · Biochemistry · doi:10.1021/bi00897a032 · Cited by 572 · see citing works

Hormonal Stimulation of Phosphatidylinositol Breakdown, with Particular Reference to the Hepatic Effects of Vasopressin

Michell, R. H., Kirk, C. J., & BILLAH, M. M. (1979) · Biochemical Society Transactions · doi:10.1042/bst0070861 · Cited by 440 · see citing works

The Synthesis of Oxytocin1

du Vigneaud, V., Ressler, C., SWAN, J. M., Roberts, C. W., & Katsoyannis, P. G. (1954) · Journal of the American Chemical Society · doi:10.1021/ja01641a004 · Cited by 422 · see citing works

Vasopressin and oxytocin receptors in the central nervous system

Tribollet, E., & Barberis, C. (1996) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v10.i1.60 · Cited by 399 · see citing works

Extrapituitary expression of the rat V1b vasopressin receptor gene.

Lolait, S. J., O’Carroll, A., Mahan, L. C., Felder, C. C., Button, D. C., Young, W. S., Mezey, É., & Brownstein, M. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6783 · Cited by 337 · see citing works

Vasopressin-Stimulated Release of Atriopeptin: Endocrine Antagonists in Fluid Homeostasis

Manning, P. T., SCHWARTZ, D. B., Katsube, N. C., Holmberg, S. W., & Needleman, P. (1985) · Science · doi:10.1126/science.2990050 · Cited by 310 · see citing works

Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression

van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306 · see citing works

Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis.

Jard, S., Gaillard, R. C., Guillon, G., Marie, J., Schoenenberg, P., Muller, A. F., Manning, M., & Sawyer, W. H. (1986) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10336-2 · Cited by 276 · see citing works

Immunohistochemical Localization of the Vasopressin V1b Receptor in the Rat Brain and Pituitary Gland: Anatomical Support for Its Involvement in the Central Effects of Vasopressin

Hernando, F., Schoots, O., Lolait, S. J., & Burbach, J. P. H. (2001) · Endocrinology · doi:10.1210/endo.142.4.8067 · Cited by 275 · see citing works

THE QUANTITATIVE ASSAY OF VASOPRESSIN

Dekanski, J. (1952) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1952.tb00723.x · Cited by 259 · see citing works

125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH29]OVT: a selective oxytocin receptor ligand

Elands, J., Barberis, C., Jard, S., Tribollet, E., Dreifuss, J.-J., Bankowski, K., Manning, M., & Sawyer, W. H. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90778-9 · Cited by 245 · see citing works

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1122 · Cited by 211 · see citing works

The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists

Thibonnier, M., Coles, P., Thibonnier, A., & Shoham, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.175 · Cited by 146 · see citing works

Structural Changes in the Arginine Vasopressin Molecule that Enhance Antidiuretic Activity and Specificity1

Sawyer, W. H., Acosta, M., Baláspiri, L., JUDD, J., & Manning, M. (1974) · Endocrinology · doi:10.1210/endo-94-4-1106 · Cited by 135 · see citing works

Primary culture of adrenal medullary chromaffin cells in a chemically defined medium

Wilson, S. P., & Viveros, O. H. (1981) · Experimental Cell Research · doi:10.1016/0014-4827(81)90366-9 · Cited by 130 · see citing works

Vasopressin stimulates steroid secretion in human adrenal glands: comparison with angiotensin-II effect

Guillon, G., Trueba, M., BRESSION, D., Grazzini, E., Chouinard, L. A., Côté, M., PAYET, M. D., Manzoni, O. J., Barberis, C., & Robert, M. (1995) · Endocrinology · doi:10.1210/endo.136.3.7867583 · Cited by 127 · see citing works

Structural Requirements for Activation of Vasopressin-sensitive Adenylate Cyclase, Hormone Binding, and Antidiuretic Actions: Effects of Highly Potent Analogues and Competitive Inhibitors

Butlen, D., Guillon, G., Rajerison, R. M., Jard, S., Sawyer, W. H., & Manning, M. (1978) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13565-7 · Cited by 122 · see citing works

Regulation of Pituitary Vasopressin Receptors during Chronic Stress: Relationship to Corticotroph Responsiveness

Aguilera, G., Pham, Q., & Rabadan‐Diehl, C. (1994) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1994.tb00586.x · Cited by 96 · see citing works

Solid‐phase synthesis of somatostatin and glucagon‐selective analogs in gram quantities

Rivier, J., Kaiser, R., & Galyean, R. (1978) · Biopolymers · doi:10.1002/bip.1978.360170809 · Cited by 87 · see citing works

Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla

Grazzini, E., Lodboerer, A. M., Pérez‐Martin, A., BRESSION, D., & Guillon, G. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756565 · Cited by 87 · see citing works

Regulation of Pituitary Vasopressin V1b Receptor mRNA during Stress in the Rat

Rabadan‐Diehl, C., Lolait, S. J., & Aguilera, G. (1995) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.1995.tb00734.x · Cited by 86 · see citing works

1-desamino-8-d-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor

Saito, M., Tahara, A., & Sugimoto, T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00070-1 · Cited by 82 · see citing works

The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15

Manning, M., Wuu, T.-C., & Baxter, J. W. M. (1968) · Journal of Chromatography A · doi:10.1016/0021-9673(68)85065-4 · Cited by 78 · see citing works

In Vivo Adrenocorticotropin-Releasing Activity of Neurohypophyseal Hormones and Their Analogs*

Aizawa, T., YASUDA, N., Greer, M. A., & Sawyer, W. H. (1982) · Endocrinology · doi:10.1210/endo-110-1-98 · Cited by 73 · see citing works

Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor

de la Cotte, N., Balestre, M., Phalipou, S., Hibert, M., Manning, M., Barberis, C., & Mouillac, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29462 · Cited by 72 · see citing works

Molecular pharmacology of AVP and OT receptors and therapeutic potential

Barberis, C., Morin, D., Durroux, T., Mouillac, B., Guillon, G., Seyer, R., Hibert, M., Tribollet, E., & Manning, M. (1999) · Drug News & Perspectives · doi:10.1358/dnp.1999.12.5.863621 · Cited by 71 · see citing works

Synthesis and some pharmacological properties of deamino[4-threonine,8-D-arginine]vasopressin and deamino[8-D-arginine]vasopressin, highly potent and specific antidiuretic peptides, and [8-D-arginine]vasopressin and deamino-arginine-vasopressin

Manning, M., Baláspiri, L., Moehring, J., Haldar, J., & Sawyer, W. H. (1976) · Journal of Medicinal Chemistry · doi:10.1021/jm00228a023 · Cited by 62 · see citing works

Solid phase synthesis of [1-deamino,4-valine]-8-D-arginine-vasopressin (DVDAVP), a highly potent and specific antidiuretic agent possessing protracted effects

Manning, M., Baláspiri, L., Acosta, M., & Sawyer, W. H. (1973) · Journal of Medicinal Chemistry · doi:10.1021/jm00267a004 · Cited by 59 · see citing works

Vasopressin: A potent autocrine/paracrine regulator of mammal adrenal functions.

Guillon, G., Grazzini, E., Andrez, M., Breton, C., Trueba, M., Gal, C. S.-L., Boccara, G., Derick, S., Chouinard, L., & Gallo-payet, N. (1998) · Endocrine Research · doi:10.3109/07435809809032672 · Cited by 55 · see citing works

Role of Glucocorticoids in the Response of the Hypothalamo-Corticotrope, Immune and Adipose Systems to Repeated Endotoxin Administration

Chautard, T., Spinedi, E., Voirol, M., Pralong, F. P., & Gaillard, R. C. (1999) · Neuroendocrinology · doi:10.1159/000054438 · Cited by 52 · see citing works

Characterization of bradykinin-stimulated release of noradrenaline from cultured bovine adrenal chromaffin cells.

Owen, P. J., Plevin, R. J., & Boarder, M. R. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24145-3 · Cited by 50 · see citing works

Vasopressin receptors. A historical survey.

Jard, S. (1998) · PubMed · Cited by 48 · see citing works

A POTENT NEW SYNTHETIC ANALOG OF VASOPRESSIN WITH RELATIVE AGONIST SPECIFICITY FOR THE PITUITARY

Schwartz, J., Derdowska, I., Sobocińska, M. K., & Kupryszewski, G. (1991) · Endocrinology · doi:10.1210/endo-129-2-1107 · Cited by 36 · see citing works

Characterization of specific V1a vasopressin-binding sites on a rat mammary-tumour-cell line

Guillon, G., Kirk, C. J., & Balestre, M. N. (1986) · Biochemical Journal · doi:10.1042/bj2400189 · Cited by 34 · see citing works

Pharmacological characterization of F‐180: a selective human V1a vasopressin receptor agonist of high affinity

Andrés, M., Trueba, M., & Guillon, G. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704634 · Cited by 33 · see citing works

Glucose- and concentration-dependence of vasopressin-induced hormone release by mouse pancreatic islets

Gao, Z.-Y., Gérard, M., & Henquin, J. (1992) · Regulatory Peptides · doi:10.1016/0167-0115(92)90075-6 · Cited by 28 · see citing works

Biologic assays for oxytocin and vasopressin.

Wh, S. (1961) · PubMed · Cited by 22 · see citing works

Mechanisms of phospholipase C activation: a comparison with the adenylate cyclase system

Guillon, G., Balestre, M., Mouillac, B., Berrada, R., & Kirk, C. J. (1987) · Biochimie · doi:10.1016/0300-9084(87)90026-5 · Cited by 18 · see citing works

An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids

Stoev, S., Cheng, L., Olma, A., Kliś, W. A., Manning, M., Sawyer, W. H., Wo, N. C., & Chan, W. Y. (1999) · Journal of Peptide Science · doi:10.1002/(sici)1099-1387(199903)5:3 · Cited by 17 · see citing works

The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors

Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 555 · see citing works

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423 · see citing works

Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men

Rilling, J. K., DeMarco, A. C., Hackett, P. D., Thompson, R., Ditzen, B., Patel, R., & Pagnoni, G. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.013 · Cited by 303 · see citing works

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents☆

MANNING, M., STOEV, S., CHINI, B., DURROUX, T., MOUILLAC, B., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00437-8 · Cited by 296 · see citing works

Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery

Song, Z., & Albers, H. E. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2017.10.004 · Cited by 244 · see citing works

Species, sex and individual differences in the vasotocin/vasopressin system: relationship to neurochemical signaling in the social behavior neural network

Albers, H. E. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.07.001 · Cited by 200 · see citing works

Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges

Chini, B., & Manning, M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350737 · Cited by 123 · see citing works

Neurohypophyseal hormones manipulation modulate social and anxiety-related behavior in zebrafish

Braida, D., Donzelli, A., Martucci, R., Capurro, V., Busnelli, M., Chini, B., & Sala, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2482-2 · Cited by 116 · see citing works

The vasopressin Avpr1b receptor: Molecular and pharmacological studies

Roper, J. A., O'Carroll, A.-M., Young, W. S., & Lolait, S. (2010) · Stress · doi:10.3109/10253890.2010.512376 · Cited by 116 · see citing works

Effect of Exercise Training on Autonomic Derangement and Neurohumoral Activation in Chronic Heart Failure

Gademan, M. G. J., Swenne, C. A., Verwey, H. F., van der Laarse, A., Maan, A. C., van de Vooren, H., PELT, J. V., van Exel, H. J., Lucas, C., Cleuren, G. V. J., et al. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.12.006 · Cited by 109 · see citing works

Excitatory action of hypocretin/orexin on neurons of the central medial amygdala

Bisetti, A., Cvetkovic, V., Serafin, M., Bayer, L., Machard, D., Jones, B. E., & Mühlethaler, M. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.07.018 · Cited by 97 · see citing works

Functional and Pharmacological Characterization of the First Specific Agonist and Antagonist for the V1b Receptor in Mammals

Claudine, S.-L. G., Derick, S., Brossard, G., Maurice, M., Simiand, J., Rolf, G., Griebel, G., & Guillon, G. (2003) · Stress · doi:10.1080/1025389032000114524 · Cited by 92 · see citing works

G PROTEIN‐COUPLED RECEPTORS

Alexander, S., Mathie, A. A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_3.x · Cited by 88 · see citing works

Conopressin-T from Conus tulipa Reveals an Antagonist Switch in Vasopressin-like Peptides

Dutertre, S., Croker, D. E., Daly, N. L., Andersson, Å., Muttenthaler, M., Lumsden, N. G., Craik, D. J., Alewood, P. F., Guillon, G., & Lewis, R. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706477200 · Cited by 83 · see citing works

Effects of oxytocin and vasopressin on the neural response to unreciprocated cooperation within brain regions involved in stress and anxiety in men and women.

Chen, X., Hackett, P. D., DeMarco, A. C., Feng, C., Stair, S., Haroon, E., Ditzen, B., Pagnoni, G., & Rilling, J. K. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9411-7 · Cited by 81 · see citing works

A Novel C-terminal Motif Is Necessary for the Export of the Vasopressin V1b/V3 Receptor to the Plasma Membrane

Robert, J., Clauser, É., PETIT, P. X., & Ventura, M. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410655200 · Cited by 76 · see citing works

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist

Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 60 · see citing works

V1b and CRHR1 Receptor Heterodimerization Mediates Synergistic Biological Actions of Vasopressin and CRH

Murat, B., Devost, D., Andrés, M., Mion, J., Boulay, V., Corbani, M., Zingg, H. H., & Guillon, G. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1202 · Cited by 53 · see citing works

The Role of Vasopressin in Hypothalamo‐Pituitary‐Adrenal Axis Activation during Stress: An Assessment of the Evidence

Makara, G. B., Mergl, Z., & Zelena, D. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.018 · Cited by 51 · see citing works

Mapping the Binding Site of Arginine Vasopressin to V 1a and V 1b Vasopressin Receptors

Rodrigo, J., Peña, A., Murat, B., Trueba, M., Durroux, T., Guillon, G., & Rognan, D. (2006) · Molecular Endocrinology · doi:10.1210/me.2006-0202 · Cited by 43 · see citing works

Oxytocin and vasopressin signaling in health and disease

Perisic, M., Woolcock, K., Hering, A., Mendel, H. C., & Muttenthaler, M. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.01.010 · Cited by 40 · see citing works

OXTR methylation modulates exogenous oxytocin effects on human brain activity during social interaction

Chen, X., Nishitani, S., Haroon, E., Smith, A. K., & Rilling, J. K. (2019) · Genes Brain & Behavior · doi:10.1111/gbb.12555 · Cited by 38 · see citing works

Presence of functional vasopressin receptors in spinal ventral horn neurons of young rats: a morphological and electrophysiological study

Liu, X., Tribollet, E., Ogier, R., Barberis, C., & Raggenbass, M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02625.x · Cited by 38 · see citing works

Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors

Peña, A., Murat, B., Trueba, M., Ventura, M. A., Bertrand, G., Cheng, L., Stoev, S. B., Szeto, H. H., Wo, N. C., Brossard, G., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1633 · Cited by 37 · see citing works

Intracellular Calcium Increase and Somatodendritic Vasopressin Release by Vasopressin Receptor Agonists in the Rat Supraoptic Nucleus: Involvement of Multiple Intracellular Transduction Signals

Sabatier, N., Shibuya, I., & Dayanithi, G. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01155.x · Cited by 36 · see citing works

Biological characterization of rodent and human vasopressin V_1breceptors using SSR-149415, a nonpeptide V_1breceptor ligand

Gal, C. S.-L., Raufaste, D., Derick, S., Blankenstein, J., Allen, J., Pouzet, B., Pascal, M., Wagnon, J., & Ventura, M. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00062.2007 · Cited by 35 · see citing works

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

Guillon, G., Derick, S., Peña, A., Cheng, L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., et al. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01163.x · Cited by 35 · see citing works

Design of Potent and Selective Agonists for the Human Vasopressin V1bReceptor Based on Modifications of [Deamino-Cys]arginine Vasopressin at Position 4

Cheng, L., Stoev, S. B., Manning, M., Derick, S., Peña, A., Mimoun, M. B., & Guillon, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030611c · Cited by 32 · see citing works

Oxytocin and vasopressin enhance synaptic transmission in the hypoglossal motor nucleus of young rats by acting on distinct receptor types

Wrobel, L. J., Reymond, I., Dupré, A., & Raggenbass, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.11.001 · Cited by 31 · see citing works

Neuroanatomical distribution and function of the vasopressin V1B receptor in the rat brain deciphered using specific fluorescent ligands

Corbani, M., Marir, R., Trueba, M., Chafaï, M., Vincent, A., Borie, A. M., Desarménien, M. G., Ueta, Y., Corbani, M., Olma, A., et al. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.10.011 · Cited by 31 · see citing works

Vasopressin modulates lateral septal network activity via two distinct electrophysiological mechanisms

Allaman‐Exertier, G., Reymond‐Marron, I., Tribollet, E., & Raggenbass, M. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05866.x · Cited by 31 · see citing works

Attenuated Stress Response to Acute Restraint and Forced Swimming Stress in Arginine Vasopressin 1b Receptor Subtype (Avpr1b) Receptor Knockout Mice and Wild‐Type Mice Treated with a Novel Avpr1b Receptor Antagonist

Roper, J. A., Craighead, M. W., O'Carroll, A.-M., & Lolait, S. J. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.02070.x · Cited by 28 · see citing works

Design and Synthesis of the First Selective Agonists for the Rat Vasopressin V 1b Receptor: Based on Modifications of Deamino-[Cys]arginine Vasopressin at Positions 4 and 8

Peña, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L., Stoev, S. B., Guillon, G., & Manning, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060928n · Cited by 27 · see citing works

Vasopressin and Oxytocin

Zingg, H. H., Bourque, C. W., & Bichet, D. G. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4871-3 · Cited by 27 · see citing works

Design, Synthesis, and Pharmacological Characterization of Fluorescent Peptides for Imaging Human V1b Vasopressin or Oxytocin Receptors

Corbani, M., Trueba, M., Stoev, S. B., Murat, B., Mion, J., Boulay, V., Guillon, G., & Manning, M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1016208 · Cited by 25 · see citing works

Characterization of a novel and selective V1B receptor antagonist

Craighead, M. W., Milne, R. J., Campbell-Wan, L., WATSON, L., Presland, J. P., THOMSON, F. J., Marston, H. M., & MacSweeney, C. P. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00440-8 · Cited by 25 · see citing works

Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor

Derick, S., Peña, A., Durroux, T., Wagnon, J., Gal, C. S., Hibert, M., Rognan, D., & Guillon, G. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0124 · Cited by 24 · see citing works

Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile

Colson, P. H., Virsolvy, A., Gaudard, P., Charrabi, A., Corbani, M., Manière, M., Richard, S., & Guillon, G. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.027 · Cited by 22 · see citing works

Effects of Neurointermediate Pituitary Lobectomy and Desmopressin on Acute Experimental Autoimmune Encephalomyelitis in Lewis Rats

Quintanar‐Stephano, A., Organista‐Esparza, A., Chavira‐Ramírez, R., Kovács, K., & Berczi, I. (2012) · NeuroImmunoModulation · doi:10.1159/000330578 · Cited by 21 · see citing works

Nature-inspired dimerization as a strategy to modulate neuropeptide pharmacology exemplified with vasopressin and oxytocin

Dekan, Z., Kremsmayr, T., Keov, P., Godin, M., Teakle, N., Duerrauer, L., Xiang, H., Gharib, D., Bergmayr, C., Hellinger, R., et al. (2021) · Chemical Science · doi:10.1039/d0sc05501h · Cited by 19 · see citing works

The vasopressin‐induced excitation of hypoglossal and facial motoneurons in young rats is mediated by V1a but not V1b receptors, and is independent of intracellular calcium signalling

Reymond, I., Tribollet, E., & Raggenbass, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05038.x · Cited by 19 · see citing works

VRQ397 (CRAVKY): a novel noncompetitive V2 receptor antagonist

Řihakova, L., Quiniou, C., Hamdan, F. F., Kaul, R., Brault, S., Hou, X., Lahaie, I., Sapieha, P. S., Hamel, D., Shao, Z., et al. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.90766.2008 · Cited by 18 · see citing works

Vasopressin increases GAGA binding activity to the V1b receptor promoter through transactivation of the MAP kinase pathway

Volpi, S., Liu, Y., & Aguilera, G. (2006) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01995 · Cited by 17 · see citing works

Arginine vasopressin in vasodilatory shock: effects on metabolism and beyond

Dünser, M. W., & Westphal, M. (2008) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e3282f4571a · Cited by 16 · see citing works

Vasopressin facilitates glycinergic and GABAergic synaptic transmission in developing hypoglossal motoneurons

Reymond, I., Raggenbass, M., & Zaninetti, M. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.03996.x · Cited by 16 · see citing works

Identified Motoneurons Involved in Sexual and Eliminative Functions in the Rat Are Powerfully Excited by Vasopressin and Tachykinins

Ogier, R., Tribollet, E., Suarez, P., & Raggenbass, M. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3364-06.2006 · Cited by 16 · see citing works

Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms

Andrés, M., Peña, A., Derick, S., Raufaste, D., Trojnar, J., Wiśniewski, K., Trueba, M., Gal, C. S., & Guillon, G. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.08.026 · Cited by 13 · see citing works

Oxytocin receptor ligands: a survey of the patent literature

Gimpl, G. (2008) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.18.11.1239 · Cited by 13 · see citing works

Position 4 analogues of [deamino-Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity

Guillon, G., Peña, A., Murat, B., Derick, S., Trueba, M., Ventura, M. A., Szeto, H. H., Wo, N. C., Stoev, S. B., Cheng, L., et al. (2005) · Journal of Peptide Science · doi:10.1002/psc.710 · Cited by 11 · see citing works

Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Bichet, D. G., Bouvier, M., Chini, B., Gimpl, G., Guillon, G., Kimura, T., Knepper, M. A., Lolait, S. J., Manning, M., Mouillac, B., et al. (2019) · IUPHAR/BPS Guide to Pharmacology CITE · doi:10.2218/gtopdb/f66/2019.4 · Cited by 8 · see citing works

Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist

Marir, R., Virsolvy, A., Wiśniewski, K., Mion, J., Haddou, D., Galibert, E., Meraïhi, Z., Desarménien, M. G., & Guillon, G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12249 · Cited by 8 · see citing works

V1b Receptors: New Probes for Therapy

Arban, R. (2007) · Endocrinology · doi:10.1210/en.2007-0735 · Cited by 8 · see citing works

Liver cirrhosis reversion is improved in hamsters with a neurointermediate pituitary lobectomy

Quintanar‐Stephano, A., Ventura‐Juárez, J., Sánchez‐Alemán, E., Aldaba-Muruato, L. R., Cervantes‐García, D., González‐Blas, D., & Muñoz‐Ortega, M. H. (2017) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2017.04.006 · Cited by 6 · see citing works

Arginine Vasopressin: An Immunoregulatory Hormone

Quintanar‐Stephano, A., Organista‐Esparza, A., Chavira‐Ramírez, R., Campos‐Rodríguez, R., Berczi, I., & Kovács, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801770-8.00005-7 · Cited by 3 · see citing works

Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells

Perdonà, E., Arban, R., & Griffante, C. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.003 · Cited by 2 · see citing works

Posterior Pituitary Agents☆

Furman, B. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98046-2 · Cited by 1 · see citing works

Endocrine and Metabolic Agents

Furman, B. L. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse024 · Cited by 1 · see citing works

Desensitisation of the Pituitary Vasopressin Receptor: Development and Use of a Stably-Transfected Model Cell System to Assess the Role of G Protein-Coupled Receptor Kinases

Cummings, S. A. (2011) · UC Research Repository (University of Canterbury) · doi:10.26021/8934 · Cited by 1 · see citing works

A Surprise End to 20 Year Search for Selective Agonists for Rat Vasopressin V1b Receptor

Manning, M., Cheng, L., Stoev, S. B., Wo, N. C., Szeto, H. H., Peña, A., Murat, B., Trueba, M., Ventura, M. A., & Guillon, G. (2010) · Springer eBooks · doi:10.1007/978-0-387-26575-9_292 · Cited by 1 · see citing works

7TM RECEPTORS

(2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00501.x · Cited by 1 · see citing works

Etude des propriétés fonctionnelles de variants de polymorphisme du récepteur V1B de la vasopressine détectés dans les troubles affectifs

Manière, M. (2015) · theses.fr (ABES) · doi:10.70675/0be8e854za3f5z48bcz81c6zbe779562a135 · Cited by 1 · see citing works

Selective Agonists for the Human Vasopressin V1b Receptor are Potent Antidiuretic Agonists in the Rat

Stoev, S. B., Cheng, L., Manning, M., Wo, N. C., Szeto, H. H., Peña, A., Murat, B., Derick, S., Trueba, M., Ventura, M. A., et al. (2010) · Springer eBooks · doi:10.1007/978-0-387-26575-9_249 · Cited by 1 · see citing works

V-2 Vasopressin Receptor

Barberis, C., & Mouillac, B. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60354-x

Posterior Pituitary Agents

Furman, B. L. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.61059-1

Cross-talk between the Oxytocin and Vasopressin Systems in the Brian: Roles in Social Behavior

Song, Z. (2022) · Digital Archive @ GSU · doi:10.57709/7996120

d[D-3-Pal2]VP

Barberis, C. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.61537-5

Vasopressin and oxytocin

Yoshida, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00501_64.x

Estudo do enriquecimento ambiental na recompensa e na modulação do sistema de oxitocina.

Rae, M. B. (2020) · doi:10.11606/t.42.2020.tde-24012020-113021

Peptide synthesis

Elmore, D. T. (2007) · Royal Society of Chemistry eBooks · doi:10.1039/b700155j

Vasopressin & Oxytocin

Alexander, S. P. H., Mathie, A. A., & Peters, J. A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706549

V-1B Vasopressin Receptor

Barberis, C., & Mouillac, B. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60356-3

Effects of Arginine Vasopressin on Islet Cells in Pancreatic Tissue Slices: Glucose-Dependent Modulation of Alpha and Beta Cell ActivityPreprint

Kerčmar, J., Murko, N., Bombek, L. K., Leitgeb, E. P., Pfabe, J. U., Postić, S., Huang, Y., Stožer, A., Korošak, D., Kozisek, X., et al. (2025) · eLife · doi:10.7554/elife.106679

Effects of Arginine Vasopressin on Islet Cells in Pancreatic Tissue Slices: Glucose-Dependent Modulation of IP3 Receptor-Specific ResponsesPreprint

Kerčmar, J., Murko, N., Bombek, L. K., Leitgeb, E. P., Pfabe, J. U., Postić, S., Huang, Y., Stožer, A., Korošak, D., Kozisek, X., et al. (2025) · eLife · doi:10.7554/elife.106679.1

Caractérisation d’outils pharmacologiques pour l’étude des récepteurs centraux de la vasopressine

Marir, R. (2013) · doi:10.70675/547ee25cz6fbfz417azabc9z92de6a7a2fcc

Conséquences pharmacologiques et fonctionnelles de l'hétérodimérisation des récepteurs V1B et CRF1

Mion, J. (2013) · theses.fr (ABES) · doi:10.70675/91d47531z8447z44d1z9f7ezf39a8e060318

Recherche ou développement, et caractérisation fonctionnelle et structurale d'effecteurs peptidiques de deux récepteurs membranaires à incidences physiopathologiques

Mebarki, L. (2017) · doi:10.70675/87833250z6f26z47bdzb2b1z8ad783ed6ef0

BindingDB Entry 50037312: Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.

BindingDB (2012) · UC San Diego · doi:10.7270/q2gf0v8c

BindingDB Entry 50037828: Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

BindingDB (2012) · UC San Diego · doi:10.7270/q2g161nh

BindingDB Entry 50033246: Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.

BindingDB (2011) · UC San Diego · doi:10.7270/q23b60gj

Pharmacological and Physiological Characterization of d[Leu4, Lys8]Vasopressin, the First V1b-Selective Agonist for Rat Vasopressin/Oxytocin Receptors

Peña, A., Murat, B., Trueba, M., Ventura, M. A., Bertrand, G., Cheng, L., Stoev, S. B., Szeto, H. H., Wo, N. C., Brossard, G., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1633 · Cited by 37 · see citing works

Design and Synthesis of the First Selective Agonists for the Rat Vasopressin V 1b Receptor: Based on Modifications of Deamino-[Cys]arginine Vasopressin at Positions 4 and 8

Peña, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L., Stoev, S. B., Guillon, G., & Manning, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060928n · Cited by 27 · see citing works

Position 4 analogues of [deamino-Cys1] arginine vasopressin exhibit striking species differences for human and rat V2/V1b receptor selectivity

Guillon, G., Peña, A., Murat, B., Derick, S., Trueba, M., Ventura, M. A., Szeto, H. H., Wo, N. C., Stoev, S. B., Cheng, L., et al. (2005) · Journal of Peptide Science · doi:10.1002/psc.710 · Cited by 11 · see citing works

Design of Potent and Selective Agonists for the Human Vasopressin V1bReceptor Based on Modifications of [Deamino-Cys]arginine Vasopressin at Position 4

Cheng, L., Stoev, S. B., Manning, M., Derick, S., Peña, A., Mimoun, M. B., & Guillon, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030611c · Cited by 32 · see citing works

Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist

Griffante, C., Green, A., Curcuruto, O., Haslam, C. P., Dickinson, B. A., & Arban, R. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706383 · Cited by 60 · see citing works